---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-177406"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:15:14.197779+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma CAO Louise Kooij to depart Aug 31, 2026; severance terms set

## Summary
- Louise Kooij to step down as Chief Accounting Officer effective August 31, 2026.
- Separation agreement includes 12 months base salary lump sum and pro-rated 2026 bonus.
- Vesting of outstanding stock options and RSUs extended to Jan 10, 2027; exercise period to Feb 10, 2027.
- Agreement includes confidentiality, non-compete, non-disparagement covenants and claims release.

## SEC filing metadata
- accession: 0001193125-26-177406
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/0001193125-26-177406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/nams-20260420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-177406
- JSON: https://secwatch.observer/filing/0001193125-26-177406.json
- Plain text: https://secwatch.observer/filing/0001193125-26-177406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.